Skip to main content

Table 1 Clinical characteristics of colon adenocarcinoma patients

From: Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

Feature Classification n (%)
Sex Male 80 (65)
  Female 43 (35)
Age ≥50 years 116 (94.3)
  <50 years 7 (5.7)
Tumor differentiation grade Well differentiated 37 (31.6)
  Moderately differentiated 59 (50.4)
  Poorly differentiated 21 (17.9)
Tumor stage I 14 (11.5)
  II 44 (36.1)
  III 49 (40.2)
  IV 15 (12.3)
Radiotherapy treatment Did not receive radiotherapy 96 (87.3)
  Received radiotherapy 14 (12.7)
Chemotherapy treatment Did not receive chemotherapy 47 (38.8)
  Received chemotherapy 74 (61.2)
Treatment No chemotherapy or radiotherapy 40 (36.4)
  Some treatment 70 (63.6)
Treatment response Response 61 (58.1)
  No response 44 (41.9)
Last follow-up status Alive without disease 66 (65.3)
  Alive with disease 17 (16.8)
  Disease progression and death 18 (17.8)
  1. Sample size for sex and age (n = 123), for tumor differentiation grade (n = 117), for tumor stage (n = 122), for radiotherapy treatment (n = 110), for chemotherapy treatment (n = 121), for a treatment (n = 110), for treatment response (n = 105) and last follow-up status (n = 101).
\